NCT04127578: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 32 planned
- Started
- 3 Jan 2020
- Primary completion
- 31 Aug 2031
- Arms
- Dose Level 1, Dose Level 2
- Results
- None posted
- 15 Oct 2019: Trial registered
- 3 Jan 2020: Trial started